The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma

References

• The Japan Glaucoma SocietyGuidelines for Glaucoma 3rd editionJ Jpn Ophthalmol Soc20121161346 Japanese
   Google Scholar
• KonstasAGQuarantaLBozkurtB24-h Efficacy of Glaucoma treatment optionsAdv Ther201633448151726909513
   PubMed Web of Science ®Google Scholar
• KonstasAGMantzirisDACateEAStewartWCEffect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucomaArch Ophthalmol199711589759799258218
   PubMedGoogle Scholar
• OrzalesiNRossettiLInvernizziTBottoliAAutelitanoAEffect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertensionInvest Ophthalmol Vis Sci20004192566257310937568
   PubMed Web of Science ®Google Scholar
• StewartWCKonstasAGNelsonLAKruftBMeta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicinesOphthalmology200811571117112218082886
   PubMed Web of Science ®Google Scholar
• NakamotoKYasudaNNannoMKinohiraYMuraiKFukudaTEffect of latanoprost on diurnal variations of intraocular pressure in normal-tension glaucomaNippon Ganka Gakkai Zasshi20031079530534 Japanese14531313
   PubMedGoogle Scholar
• KonstasAGBoboridisKGKapisP24-Hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapyAdv Ther201734122123527913991
   PubMed Web of Science ®Google Scholar
• KonstasAGQuarantaLKatsanosATwenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertensionBr J Ophthalmol201397121510151523681371
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670173012049574
   PubMed Web of Science ®Google Scholar
• KuwayamaYDE-111 collaborative trial group. [Phase III double-masked study of fixed combination tafluprost 0.0015%/timolol 0.5% (DE-111) versus tafluprost 0.0015% alone or given concomitantly with timolol 0.5% in primary open angle glaucoma and ocular hypertension]J Eye (Atarashii Ganka)201330811851194 Japanese
   Google Scholar
• HollóGHommerAAntón LópezARopoAEfficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredientsJ Ocul Pharmacol Ther201430646847524738883
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHusseinMFactors for glaucoma progression and the effect of treatment: the early manifest glaucoma trialArch Ophthalmol20031211485612523884
   PubMedGoogle Scholar
• DiestelhorstMLarssonLIEuropean Latanoprost Fixed Combination Study GroupEuropean latanoprost fixed combination study group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertensionBr J Ophthalmol200488219920314736774
   PubMed Web of Science ®Google Scholar
• DiestelhorstMLarssonLIEuropean-Canadian latanoprost fixed combination study groupA 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual componentsOphthalmology20061131707616263174
   PubMed Web of Science ®Google Scholar
• SchumanJSKatzGJLewisRAEfficacy and safety of fixed combination of travoprost 0.004%/timolol 0.5% ocular hypertensionAm J Ophthalmol2005140224225016086946
   PubMed Web of Science ®Google Scholar
• HughesBABacharachJCravenERA three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertensionJ Glaucoma200514539239916148589
   PubMed Web of Science ®Google Scholar
• NucciCVaresiCMartucciAEfficacy of timolol 0.1% gel and a prostaglandin analog in an unfixed combination compared to the corresponding fixed combinationsEur J Ophthalmol201323568368923640513
   PubMed Web of Science ®Google Scholar
• QuarantaLBiagioliERivaIProstaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysisJ Ocul Pharmacol Ther201329438238923231442
   PubMed Web of Science ®Google Scholar
• KitazawaYAzumaITsukaharaSKomemushiSClinical evaluation of Timolol GS once-a-day ophthalmic solution in primary open-angle glaucoma and ocular hypertension. Phase III comparative study with Timolol twice-a-day ophthalmic solution as control drugJ Eye (Atarashii Ganka)1996131143154 Japanese
   Google Scholar
• RolleTCurtoDAlovisiCFranzoneMBrogliattiBGrignoloFMTimogel vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptanceEur J Ophthalmol2012221283322167540
   PubMed Web of Science ®Google Scholar
• EastyDLNemeth-WasmerGVounatsosJPComparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patientsBr J Ophthalmol200690557457816622086
   PubMed Web of Science ®Google Scholar
• ÖzyolEÖzyolPThe efficacy of a latanoprost/timolol fixed combination versus latanoprost and timolol gel-forming solution unfixed combination on daytime intraocular pressureJ Glaucoma201625213513925264990
   PubMed Web of Science ®Google Scholar
• UedaKTonouchiAFukanoYAsadaHKawazuKTafluprost 0.0015%/timolol 0.5% combination ophthalmic solution (DE-111 ophthalmic solution) formulation design and intraocular penetration in ratsJ Eye (Atarashii Ganka)2013301217611766 Japanese
   Google Scholar
• FuwaMUedaKAkaishiTAdvantages of efficacy and safety of fixed-dose tafluprost/timolol combination over fixed-dose latanoprost/timolol combinationPLoS One2016117e015879727383260
   PubMed Web of Science ®Google Scholar
• Moreno-MontañésJMartínez-de-la-CasaJMSabaterALMorales-FernandezLSáenzCGarcia-FeijooJClinical evaluation of the new rebound tonometers Icare PRO and Icare ONE compared with the Goldmann tonometerJ Glaucoma201524752753224844537
   PubMed Web of Science ®Google Scholar